Teva Pharmaceutical Industries Ltd (TEVJF) EPS (Basic) (2009 - 2026)
Teva Pharmaceutical Industries' (TEVJF) quarterly EPS (Basic) came in at -$0.49 in Q2 2026, down 301.82% YoY from $0.24 in Q2 2025, and down 254.47% on a QoQ basis from $0.32 in Q1 2026.
Teva Pharmaceutical Industries Ltd (TEVJF) EPS (Basic) (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVJF) has 18 years of EPS (Basic) data on file, last reported at -$0.49 in Q2 2026.
- Quarterly EPS (Basic) fell 301.82% year-over-year to -$0.49 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $0.6 (up 510.33% YoY) and the FY2025 annual result came in at $1.23, up 170.71% from the prior year.
- EPS (Basic) fell to -$0.49 in Q2 2026, from $0.32 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $0.46 in Q1 2024 to a low of -$1.61 in Q4 2023.
- A 5-year average of -$0.26 and a median of -$0.24 in 2023 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) slumped 1278.01% — and 2024, when it jumped 303.68%.
- Tracing TEVJF's EPS (Basic) over 5 years: stood at -$1.2 in 2022, then tumbled by 33.55% to -$1.61 in 2023, then soared by 84.85% to -$0.24 in 2024, then surged by 268.82% to $0.41 in 2025, then slumped by 220.45% to -$0.49 in 2026.
- The last three EPS (Basic) figures came in at -$0.49 (Q2 2026), $0.32 (Q1 2026), and $0.41 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.49 |
| Mar 31, 2026 | 0.32 |
| Dec 31, 2025 | 0.41 |
| Sep 30, 2025 | 0.38 |
| Jun 30, 2025 | 0.24 |
| Mar 31, 2025 | 0.19 |
| Dec 31, 2024 | -0.24 |
| Sep 30, 2024 | -0.35 |
| Jun 30, 2024 | -0.77 |
| Mar 31, 2024 | 0.46 |
| Dec 31, 2023 | -1.61 |
| Sep 30, 2023 | 0.07 |
| Jun 30, 2023 | -0.81 |
| Mar 31, 2023 | -0.23 |
| Dec 31, 2022 | -1.20 |
| Sep 30, 2022 | 0.06 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.88 |
| Dec 31, 2021 | -0.14 |
| Sep 30, 2021 | 0.28 |